ClinicalTrials.gg
Status unknownNCT05755776POWERUpdated Sep 21, 2023

The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment

An observational study in Chronic Hepatitis B, sponsored by The Second Affiliated Hospital of Chongqing Medical University. Status unknown at 13 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by The Second Affiliated Hospital of Chongqing Medical University · Observational

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
204
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
72nd of 99
204 · median 500
Started
2023
with 28 others
Observational
99 of 375
34 open now
Registered
256th of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 72nd largest by planned enrollment of the 99 observational ones that give a count, is one of 29 that started in 2023, is one of 99 observational ones, and was the 256th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to explore the efficacy and safety of Tenofovir Amibufenamide (TMF) in Entecavir (ETV) treated chronic hepatitis B patients with low-level viraemia. The main question it aims to answer is:

  • The efficacy and safety of TMF in chronic hepatitis B patients with low-level viraemia.
  • What is the appropriate treatment for ETV treated chronic hepatitis B patients with low-level viraemia.

Participants will choose to maintain their original regimen (ETV) or switch to TMF After being fully informed of the benefits and risks of treatment.

Researchers will compare ETV and TMF to see if there is a difference in the efficacy of the two drugs in chronic hepatitis B patients with low-level viraemia.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

Keywords

  • Chronic Hepatitis b
  • Entecavir
  • Tenofovir Amibufenamide
  • Low-level viraemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target population was chronic hepatitis B patients with LLV (HBV DNA from 20-to 2000IU/mL) of ETV treatment from multiple centers across mainland China.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be able to understand and sign a written , which must be obtained prior to screening.
  2. Male and non-pregnant, non-lactating female subjects who have reached the age of 18-65 years (based on the date of signed informed consent). Female subjects of childbearing age with a negative serum pregnancy test.
  3. Documented signs of chronic infection (e.g., HBsAg positive for more than 6 months.
  4. Subjects treated with ETV over 1 year will be able to be enrolled in the study.
  5. Subjects with 20 ≤ HBV-DNA \< 2000 IU/mL at screening (including intermittent and continuous low-level viraeima).
  6. Must be willing and able to comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Female patients who are pregnant or breastfeeding or who plan to become pregnant during the study period.
  2. Men and women of who are unwilling to use an "effective" method of as defined in the protocol during the study period.
  3. Co-infection with HAV , , HDV or HEV; or co-infection with autologous liver, metabolism-related fatty liver, or drug-induced liver injury.
  4. Diagnosis of hepatocellular carcinoma by imaging (with evidence of hepatocellular carcinoma)
  5. Patients who have received a solid organ or bone marrow transplant
  6. History of within 5 years prior to screening, except for specific tumors cured by surgical resection (basal cell dermal skin cancer, etc.); patients evaluated for probable malignancy were ineligible.
  7. Currently receiving treatment with immunomodulators (e.g., ), drugs, nephrotoxic drugs, or drugs capable of regulating renal excretion. Drugs that modulate renal excretion.
  8. Renal, cardiovascular, pulmonary, or neurological disease that is considered severe by the investigator.
  9. Severe bone disease (e.g., osteochondrosis, chronic osteomyelitis, osteogenesis imperfecta, chondromalacia) or multiple fractures.
  10. Subjects receiving a combination drug (subjects receiving a contraindicated drug require a minimum 30-day ) and known reactions to study drugs, metabolites or formulation .
  11. Current alcohol or drug abuse that, in the investigator's judgment, may interfere with the subject's compliance with study requirements.
  12. Any other clinical condition that, in the opinion of the investigator, would render the subject unsuitable for the study or unable to comply with the dosing requirements medical condition or prior treatment.
  13. Prior or existing clinical liver failure ( score ≥ grade B).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
204 participants (estimated)
Patient registry
No

Groups and cohorts

  • ETV group

    Participants in this group will continue ETV daily until the end of the study.

  • TMF group

    Participants in this group will switch to TMF 25 mg, daily until the end of the study.

    Drug: TMF

Interventions

  • DrugTMF

    switch ETV to TMF

    Also known as: Heng Mu

06

What researchers measure

Primary outcomes

  1. The proportions of undetectable HBV DNA in patients treated with ETV and TMF at week 48.

    Undetectable HBV DNA is defined as below 20 IU/mL.

    Time frame: 48 weeks

Secondary outcomes

  1. The proportions of undetectable HBV DNA in patients treated with ETV and TMF at week 24.

    Undetectable HBV DNA is defined as below 20 IU/mL.

    Time frame: 24 weeks

  2. The proportions of ALT normalization in patients treated with ETV and TMF at week 24 and 48.

    There are two criteria for ALT normalization. Criteria1: below 40 U/L. Criteria2: Males: ALT\<30U/L, female: ALT\<19U/L.

    Time frame: 24 weeks and 48 weeks

  3. Comparing pgRNA levels from baseline at week 24 and 48.

    Time frame: 24 weeks and 48 weeks

  4. Comparing HBcrAg levels from baseline at week 24 and 48.

    Time frame: 24 weeks and 48 weeks

  5. The proportions of undetectable pgRNA in patients treated with ETV and TMF at week 24 and 48.

    Undetectable pgRNA is defined as below 100 pg/mL.

    Time frame: 24 weeks and 48 weeks

  6. The proportions of undetectable HBcrAg in patients treated with ETV and TMF at week 24 and 48.

    Time frame: 24 weeks and 48 weeks

  7. Comparing degree of liver fibrosis from baseline at week 24 and 48.

    Evaluation of liver fibrosis including Fibroscan, APRI and FIB-4.

    Time frame: 24 weeks and 48 weeks

  8. Comparing the change of creatinine clearance rate from baseline at week 24 and 48.

    Time frame: 24 weeks and 48 weeks

  9. The types, incidence and severity of adverse events and serious adverse events during treatment were evaluated in both groups

    Time frame: Week 48

07

Study locations

3 of 13 sites recruiting
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400010, China
    Recruiting
  • Chongqing University Three Gorges Central Hospital
    Chongqing, 400010, China
    Not yet recruiting
    • Xuan An · Contact
  • Affiliated Hospital of Guangxi Medical University
    Guangxi, China
    Not yet recruiting
    • Minghua Su · Contact
  • Hepatobiliary disease of Jilin Province
    Jilin, China
    Not yet recruiting
    • Hui Chen · Contact
  • The First People's Hospital of Yunnan Province
    Kunming, China
    Not yet recruiting
    • Jiawei Geng · Contact
  • the Second People's Hospital of Yunnan Province
    Kunming, China
    Not yet recruiting
    • Hui Li · Contact
  • Nanjing Second Hospital
    Nanjing, China
    Not yet recruiting
    • Wei Ye · Contact
  • The Second Hospital of Ningbo
    Ningbo, China
    Recruiting
    • Airong HU · Contact
  • Shanghai East Hospital
    Shanghai, China
    Recruiting
    • Lihong QU · Contact
  • Shuguang Hospital, Shanghai, China.
    Shanghai, China
    Not yet recruiting
    • Xuehua Sun · Contact
  • The Sixth People's Hospital of Shenyang
    Shenyang, China
    Not yet recruiting
    • Xiaofeng Wu · Contact
  • The First People's Hospital of Taicang
    Taicang, China
    Not yet recruiting
    • Yonglan Pu · Contact
  • The Fourth People's Hospital of Zibo
    Zibo, China
    Not yet recruiting
    • Gang Li · Contact
08

References and documents

Publications

  • Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019 Mar 1;97(3):230-238. doi: 10.2471/BLT.18.219469. Epub 2019 Jan 28. PubMed 30992636 ↗
  • Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006 Jan 4;295(1):65-73. doi: 10.1001/jama.295.1.65. PubMed 16391218 ↗
  • Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-1599. doi: 10.1002/hep.29800. No abstract available. PubMed 29405329 ↗
  • Sun Y, Wu X, Zhou J, Meng T, Wang B, Chen S, Liu H, Wang T, Zhao X, Wu S, Kong Y, Ou X, Wee A, Theise ND, Qiu C, Zhang W, Lu F, Jia J, You H. Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. Clin Gastroenterol Hepatol. 2020 Oct;18(11):2582-2591.e6. doi: 10.1016/j.cgh.2020.03.001. Epub 2020 Mar 6. PubMed 32147592 ↗
  • Kim JH, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology. 2017 Aug;66(2):335-343. doi: 10.1002/hep.28916. Epub 2016 Dec 24. PubMed 28012257 ↗
  • Wang J, Sheng Q, Ding Y, Chen R, Sun X, Chen X, Dou X, Lu F. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient. J Hepatol. 2018 Apr;68(4):847-849. doi: 10.1016/j.jhep.2017.10.030. Epub 2017 Nov 4. No abstract available. PubMed 29113914 ↗
  • Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011 Jul;106(7):1264-71. doi: 10.1038/ajg.2011.45. Epub 2011 Mar 1. PubMed 21364549 ↗
  • Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol. 2019 Jun;25(2):93-159. doi: 10.3350/cmh.2019.1002. Epub 2019 Jun 12. No abstract available. PubMed 31185710 ↗
  • Ogawa E, Nomura H, Nakamuta M, Furusyo N, Koyanagi T, Dohmen K, Ooho A, Satoh T, Kawano A, Kajiwara E, Takahashi K, Azuma K, Kato M, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020 Jul;40(7):1578-1589. doi: 10.1111/liv.14482. Epub 2020 Apr 30. PubMed 32304611 ↗
  • Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, Wen X, Gao Z, Huang Y, Yang D, Chen E, Mao Q, Lin S, Shang J, Gong H, Zhong L, Yin H, Wang F, Hu P, Xiao L, Li C, Wu Q, Sun C, Niu J, Hou J; TMF Study Group. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther. 2021 Nov;54(9):1134-1149. doi: 10.1111/apt.16611. Epub 2021 Sep 29. PubMed 34587302 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2024, 21 months after the start.

Of 71 observational studies under Hepatitis B, Chronic, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 99. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Mar 6, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05755776
Responsible party
Sponsor
First posted
Mar 6, 2023
Start date
Mar 1, 2023
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Sep 21, 2023

Study contacts

Jie Wu
Contact
wuj6@hspharm.com
+86 18652100702
Peng Hu, phD
study director · The Second Affiliated Hospital of Chongqing Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion